The price of life according to the HSE: €100,000 deemed ‘too expensive’ for life-saving drug for young cancer sufferer
The crumbling HSE is refusing to fund a life-saving treatment for a 34-year-old cancer sufferer for being ‘too expensive.’ At a price tag of €100,000 per patient per year, Nivolumab (commercially known as Opdivo) may …
